By administering either inactivated resected tumor lysates or allogeneic tumor-cell lysates with additional components such as adjuvants and cytokines, these cancer vaccines could present epitopes of tumor antigens to activate both CD4+ and CD8+ T cells in the human body [69,70,71]. This evidence concerns the gene CD8A and cancer.